| Literature DB >> 32657760 |
Hesheng Ou1, Hongli Teng1, Yuwang Qin1, Xuelan Luo2, Peng Yang1, Wenyu Zhang3, Wei Chen4, Dongning Lv5, Huamin Tang6.
Abstract
An intriguing area of research has demonstrated the ability of extracellular vesicles (EVs) as biological vehicles for microRNAs (miRNAs) transfer. Mesenchymal stem cells (MSCs) produce large amounts of EVs. Rat models of ischemia/reperfusion (I/R) were established to explore the expression profile of thioredoxin-interacting protein (TXNIP), which was then knocked-down to investigate its effects on myocardial remodeling, followed by detection on myocardial infarction size (MIS), myocardial collagen volume fraction (CVF) and cardiomyocyte apoptosis. MSCs-derived EVs carrying miR-150-5p were cultured with neonatal cardiomyocytes under hypoxia/hypoglycemia condition for in vitro exploration and intramyocardially injected into I/R rats for in vivo exploration. I/R-induced rats presented higher TXNIP levels and lower miR-150-5p levels, along with increased cardiomyocyte apoptosis. miR-150-5p in MSCs was transferred through EVs to cardiomyocytes, leading to suppressed myocardial remodeling, as reflected by smaller MIS and CVF and suppressed cardiomyocyte apoptosis. I/R-treated rats injected with MSCs-derived EVs containing miR-150-5p showed a reduction in myocardial remodeling associated with the downregulation of TXNIP, which may be clinically applicable for treatment of I/R.Entities:
Keywords: extracellular vesicles; ischemia/reperfusion; mesenchymal stem cells; microRNA-150-5p; myocardial remodeling
Mesh:
Substances:
Year: 2020 PMID: 32657760 PMCID: PMC7377831 DOI: 10.18632/aging.102792
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1TXNIP is highly expressed in the rat model of I/R. (A) The preoperative, intraoperative and postoperative ST segments (mV) in sham-operated rats (n = 12) (left) and in rats with I/R (n = 72) (right); * p < 0.05 vs. the preoperative ST segment; # p < 0.05 vs. the intraoperative ST segment. (B) TXNIP expression in myocardium determined by RT-qPCR; * p < 0.05 vs. the sham group (sham-operated rats). (C) TXNIP protein expression in myocardium normalized to GAPDH determined by Western blot analysis; * p < 0.05 vs. the sham group (sham-operated rats). (D) The positive expression of TXNIP in myocardium identified by immunohistochemistry (400 ×); * p < 0.05 vs. the sham group (sham-operated rats). Measurement data were presented as mean ± standard deviation. Comparison between two groups was analyzed by unpaired t-test. Comparison among multiple groups was analyzed by one-way analysis of variance, followed by Tukey’s post hoc test. n = 12.
Figure 2TXNIP knockdown impedes myocardial remodeling of rats with I/R. (A) TXNIP expression in myocardium determined by RT-qPCR. (B) TXNIP protein expression in myocardium normalized to GAPDH determined by Western blot analysis. (C) The myocardial infarct size detected by TTC staining. (D) The myocardial collagen detected by Masson's staining (200 ×). (E) The cardiomyocyte apoptosis detected by TUNEL staining (400 ×). (F) The protein expression of apoptosis-related factors (c-Jun, Bax and Bcl-2) normalized to GAPDH determined by Western blot analysis. * p < 0.05 vs. the sham group (sham-operated rats); # p < 0.05 vs. the I/R + sh-NC group (I/R rats treated with sh-NC). Measurement data were presented as mean ± standard deviation. Comparison between two groups was analyzed by non-paired t-test. n = 12.
Echocardiograph results of LVEDV, LVEDD, LVESV, LVESD, LVEEF and LVEFS by echocardiography.
| Sham | 216.12 ± 18.37 | 5.47 ± 0.23 | 85.45 ± 7.46 | 3.12 ± 0.28 | 60.29 ± 4.29 | 42.94 ± 4.67 |
| I/R | 400.23 ± 32.38* | 11.49 ± 1.11* | 287.46 ± 25.38* | 10.23 ± 1.03* | 28.18 ± 2.68* | 10.98 ± 1.10* |
| I/R + sh-NC | 401.83 ± 24.18 | 12.35 ± 1.05 | 284.88 ± 22.35 | 11.16 ± 0.95 | 29.12 ± 3.09 | 9.61 ± 0.83 |
| I/R + sh-TXNIP | 285.49 ± 24.39# | 8.18 ± 0.47# | 165.42 ± 17.56# | 5.84 ± 0.47# | 41.98 ± 4.79# | 28.65 ± 3.04# |
| I/R + EVagomir-NC | 380.48 ± 26.90 | 11.58 ± 0.34 | 259.96 ± 29.23 | 10.19 ± 0.41 | 31.84 ± 3.09 | 12.02 ± 1.49 |
| I/R + EVmiR-150-5p-agomir | 274.35 ± 19.78& | 7.95 ± 0.55& | 161.13 ± 15.83& | 6.00 ± 0.54& | 41.34 ± 2.09& | 24.50 ± 2.65& |
| I/R + EVmiR-150-5p-agomir + oe-TXNIP | 416.01 ± 19.97$ | 11.59 ± 0.32$ | 301.12 ± 22.14$ | 10.20 ± 0.39$ | 27.63 ± 3.61$ | 11.99 ± 1.49$ |
Note: * p < 0.05 vs. the sham group (sham-operated rats); # p < 0.05 vs. the I/R + sh-NC group (I/R rats treated with sh-NC); & p < 0.05 vs. the I/R + EVagomir-NC group (I/R rats treated with EVagomir-NC); $ p < 0.05 vs. the I/R + EVmiR-150-5p-agomir group (I/R rats treated with EVmiR-150-5p-agomir). The measurement data were expressed as mean ± standard deviation. Comparison among multiple groups was conducted using one-way analysis of variance, followed by Tukey’s post hoc test. I/R, ischemia/reperfusion; NC, negative control; TXNIP, thioredoxin-interacting protein; miR, microRNA; LVEDV, left ventricular end-diastolic volume; LVEDD, left ventricular end-diastolic dimension; LVESV, left ventricular end-systolic volume; LVESD, left ventricular end-systolic dimension; LVEEF, left ventricular ejection fraction; LVEFS, left ventricular fractional shortening.
Figure 3TXNIP is the target of miR-150-5p. (A) The binding sites between miR-150-5p and TXNIP as predicted by microrna.org. (B) The relative luciferase activity determined by dual-luciferase reporter gene assay. (C) The miR-150-5p expression in myocardium determined by RT-qPCR, normalized to U6; * p < 0.05 vs. the sham group (sham-operated rats); n =12. (D) The mRNA expression of TXNIP in myocardium determined by RT-qPCR, normalized to GAPDH. (E) The protein expression of TXNIP in myocardium normalized to GAPDH determined by Western blot analysis. (F) The expression of miR-150-5p in cardiomyocytes in response to miR-150-5p-agomir and miR-150-5p-antagomir determined by RT-qPCR. * p < 0.05 vs. the agomir-NC group (I/R rats treated with agomir-NC); # p < 0.05 vs. the antagomir-NC group (I/R rats treated with antagomir-NC). Measurement data were presented as mean ± standard deviation. Comparison between two groups was analyzed by unpaired t-test. The cell experiment was repeated 3 times independently.
Figure 4Cardiomyocyte apoptosis is suppressed by MSCs-derived EVs carrying miR-150-5p. (A) The images captured under transmission electron microscopy. (B) EV size measured by nanoparticle tracking analysis. (C) The expression of EV markers (CD9, CD63, Alix and GRP94) detected by Western blot analysis. (D) EV internalization detected by immunohistochemistry (400 ×). (E) PKH67-staining (FITC wavelength) in neonatal cardiomyocytes detected by flow cytometric analysis. (F) The expression of miR-150-5p in MSCs determined by RT-qPCR. (G) The expression of miR-150-5p in EVs determined by RT-qPCR. (H) neonatal cardiomyocyte apoptosis detected by TUNEL staining (200 ×). (I) The protein expression of apoptosis-related factors (c-Jun, Bax and Bcl-2) normalized to GAPDH determined by Western blot analysis. (J) The expression of miR-150-5p and TXNIP in neonatal cardiomyocytes determined by RT-qPCR. (K) TXNIP expression in neonatal cardiomyocytes normalized to GAPDH determined by Western blot analysis. (L) Transwell co-culture system under hypoxia/hypoglycemia condition. (M) Neonatal cardiomyocyte apoptosis detected by TUNEL staining (200 ×); * p < 0.05 vs. the agomir-NC group (cells treated with agomir-NC); # p < 0.05 vs. the miR-150-5p-agomir group (cells treated with miR-150-5p-agomir). * p < 0.05 vs. the agomir-NC group (cells treated with agomir-NC) or the EVagomir-NC group (cells treated with EVagomir-NC); # p < 0.05 vs. the antagomir-NC group (cells treated with antagomir-NC) or the EVantagomir-NC group (cells treated with EVantagomir-NC). Measurement data were presented as mean ± standard deviation. Comparison among multiple groups was analyzed by one-way analysis of variance, followed by Tukey’s post hoc test. The cell experiment was repeated 3 times independently.
Figure 5The EVs-loaded with miR-150-5p/TXNIP mediates myocardial remodeling after I/R. (A) The transduction efficiency detected by RT-qPCR. (B) The myocardial infarct size detected by TTC staining. (C) The myocardial collagen detected by Masson's staining (200 ×). (D) The cardiomyocyte apoptosis detected by TUNEL staining (400 ×). (E) The protein expression of apoptosis-related factors (c-Jun, Bax and Bcl-2) normalized to GAPDH determined by Western blot analysis. * p < 0.05 vs. the I/R + EVagomir-NC group (I/R rats treated with EVagomir-NC); # p < 0.05 vs. the I/R + EVmiR-150-5p-agomir group (I/R rats treated with EV miR-150-5p-agomir). Measurement data were presented as mean ± standard deviation. Comparison among multiple groups was analyzed by one-way analysis of variance, followed by Tukey’s post hoc test. n = 12.
Figure 6The schematic diagram depicts molecular basis underlying EVs derived from MSCs on I/R by transferring miR-150-5p. MSCs can secrete EVs to transfer miR-150-5p into cardiomyocytes, which further internalize EVs to release miR-150-5p and miR-150-5p protects against I/R by downregulating TXNIP and inhibiting myocardial remodeling.
Primer sequences for reverse transcription quantitative polymerase chain reaction.
| TXNIP | CTGAAGTTACCCGAGTCAAAGC | CTCACCTGTAGCCTGGTCTTCT |
| GAPDH | CTGACATGCCGCCTGGAGA | ATGTAGGCCATGAGGTCCAC |
| miR-150-5p | CGCCAGGGTTTTCCCAGTCACGACTCCCAACCCTTGTACCAGT | CGCGAGGAGAGAATTAATACGACTCAGTATACGCGCACTGGT |
| U6 | CTCGCTTCGGCAGCACA | AACGCTTCACGAATTTGCGT |
Note: TXNIP, thioredoxin-interacting protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; miR, microRNA.